In vitro cytotoxic activity of anthrapyrazole analogues in human prostate DU-145 and testicular NTERA-2 carcinoma cells

MARIA E. CUEVAS and KURT SEILHEIMER
Department of Biology, Southwestern University, Georgetown, TX 78626, USA

Received March 6, 2008; Accepted April 22, 2008

Abstract. Anthrapyrazoles are potent cytotoxic agents that intercalate into DNA, causing DNA strand breaks, inhibition of DNA synthesis and topoisomerase II. In this study, we investigated the in vitro cytotoxic activity of two anthrapyrazole analogues (AP-10 and AP-11) in human prostate (DU-145) and testicular (NTERA-2) carcinoma cells. The cytotoxic activity of these analogues was determined using the MTS cell growth inhibition assay. The IC_{50} of AP-10 on NTERA-2 and DU-145 cells was found to be 0.2 and 0.4 μM, respectively. AP-11 inhibited cell growth with an IC_{50} value of 1.2 μM (NTERA-2) and 3.2 μM (DU-145). Using trypan blue dye exclusion assay, we were able to confirm the cytotoxic effect of AP-10 and AP-11 on DU-145 cells, thereby distinguishing it from the cytostatic effect. To determine whether cells were able to recover after exposure to the anthrapyrazole analogues, DU-145 and NTERA-2 cells were exposed to the IC_{50} concentration of AP-10 and AP-11. After a 1-h exposure, fresh media containing either testosterone or dihydrotestosterone were added daily for five days and the cell growth rate was compared to the control. Although cells exposed to AP-10 and AP-11 were able to recover, they never attained the growth rate observed in the control cultures. The DNA fragmentation assay did not provide evidence of apoptosis. In conclusion, our results demonstrated that AP-10 had a higher cytotoxic activity than AP-11, and apoptosis appeared not to be involved in the biological activity of these compounds.

Introduction

Anthrapyrazoles (APs), analogues of anthracyclines, are a specific class of anti-tumor agents that were developed with the intention of lowering the high cardiotoxicity effects caused by their precursors (1). Due to their planar aromatic structure, these compounds are also considered to be exceptional DNA complexing agents (2,3). Furthermore, studies have shown that the planar anthrapyrazole compounds can cause single and double strand breaks in DNA and are also potent and selective inhibitors of DNA synthesis (4-6). Specifically, studies have shown the clinically tested anthrapyrazoles, losoxantrone and piroxantrone to exert their anticancer effects by inhibiting topoisomerase II activity in advanced breast cancer (7) and a variety of cancer cell lines (8). In addition, losoxantrone, piroxantrone and teloxantrone have proven to be effective antineoplastic drugs in the treatment of breast cancer (9), prostate cancer (10) and acute leukemia (5) but have little or no activity in gastric, colorectal and pancreatic cancers (11). The anthrapyrazole analogues AP-10 and AP-11 were synthesized in the laboratory of Dr F. Guziec (Chemistry/Biochemistry Department, Southwestern University, Georgetown, TX) to determine whether slight structural changes have an effect on compound effectiveness. Compounds AP-10 and AP-11 have two amino substituents that are protonated at a physiological pH of 7.4 and differ in the presence of a methyl group at R4 on the N-2 side chain (Fig. 1). The tertiary amino side chain was added in an attempt to increase the electrostatic interaction with DNA (12).

A study by Begleiter et al (12) determined the in vitro cytotoxic activity of newly synthesized anthrapyrazole analogues, including AP-10 and AP-11 on a variety of cell lines. Their study showed these compounds to be less potent than losoxantrone on human breast cancer (MCF-7), human pharynx squamous carcinoma (FaDu) cells, human leukemia (K562) and Chinese hamster ovarian (CHO) cells. Furthermore, the potency of AP-10 and AP-11 varies among the different cell lines. For instance, in the CHO cell line, AP-11 has a higher cytotoxic effect compared to AP-10, whereas in the K562 cell line there is no difference in their cytotoxic effects. They also demonstrated a lack of correlation between the degree of topoisomerase II inhibition and the degree of cytotoxicity observed.

Studies in our laboratory, using human mammary (MCF-7), endometrial (HEC 1A) and ovarian (SK-OV-3) adenocarcinoma cells have shown AP-10 to have a higher cytotoxic activity than AP-11 (unpublished data). The aims of this project were to investigate the cytotoxic effectiveness of AP-10 and AP-11 on prostate (DU-145) and testicular (NTERA-2-pluripotent embryonal) carcinoma cells and to determine the underlying cellular mechanism for their cytotoxicity.

There have been many approaches to the treatment of prostate and testicular cancer. For example, the inhibition of prostate cancer has been accomplished by androgen withdrawal therapy where lutenizing releasing hormone...
(LHRH) inhibitory drugs are used to decrease androgen production (13). Another approach includes the use of doxorubicin, an anthracycline antibiotic, on hormone-refractory prostate cancer producing a response rate ranging from 25 to 84% in the shrinkage or disappearance of the tumor (14). Furthermore, in a clinical setting, anthrapyrazoles such as losoxantrone have been used to treat prostate cancer with only 22% of patients responding to the treatment (10). The most common treatments for testicular cancer include surgery, radiation therapy and chemotherapy. However, these treatments result in variable degrees of damage to the germinal epithelium that leads to sub-fertility or infertility (15).

Treatments such as cisplatin-based chemotherapy, used to treat testicular germ cell cancer, have shown a recovery of spermatogenesis in ~50% of patients after two years and 80% recovery after five years. However, a number of patients become infertile and the risk increases with cisplatin dose (15,16). Furthermore, cisplatin forms covalent DNA adducts that are partially mutagenic and cause side effects, with lung toxicity being a major concern (17,18). A study by Ghosh et al (19) looked at vanadocene compounds (metallocenes) and found them to exhibit significant cytotoxicity against testicular (NTERA-2) cells, inducing apoptosis within 24 h.

In the present study we determined the IC$_{50}$ of the new compounds and the cellular mechanisms involved (15) in the inhibition of cell proliferation. Using the standard MTS cell growth inhibition assay, analogue AP-10 was found to have a higher cytotoxic activity than AP-11. Furthermore, NTERA-2 cells appeared to be more sensitive to these compounds than DU-145 cells. Finally, based on the DNA-fragmentation assay, apoptosis appeared not to be the underlying cellular mechanism of the cytotoxic effect of AP-10 and AP-11.

**Materials and methods**

*Chemicals.* Eagle’s Minimal Essential Media (EMEM) with Earle’s Basal Saline Solution (EBSS) and Dulbecco’s modified Eagle’s medium (DMEM) were purchased from American Type Culture Collection (ATCC, Manasas, VA). Fetal bovine serum (FBS) and charcoal stripped fetal bovine serum (CSFBS) were obtained from Invitrogen (Chicago, IL). L-glutamine, penicillin/streptomycin/glutamine (PSG), trypsin, sodium bicarbonate, sodium pyruvate, glucose and non-essential amino acids were from Gibco (Grand Island, NY). Testosterone and dihydrotestosterone (DHT) were purchased from Sigma (St. Louis, MO).

*Cell lines and tissue culture conditions.* Human prostate (DU-145) and testicular carcinoma cells (NTERA-2) were purchased from ATCC. DU-145 cells were maintained in EMEM with EBSS, supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 1.5 mg/ml sodium bicarbonate, 1% PSG and 10% FBS. NTERA-2 cells were maintained in DMEM with 4 mM L-glutamine, 1.5 mg/ml sodium bicarbonate and 4.5 mg/ml glucose, 1% PSG and 10% FBS. Cells were grown in 25 or 75 cm$^2$ culture flasks at 37°C in a 5% CO$_2$ atmosphere.

*Compounds.* Anthrapyrazole analogues (AP-10 and AP-11) were a generous gift from Dr Frank Guzic of the Chemistry/

Biochemistry Department at Southwestern University. AP-10 and AP-11 were dissolved in phosphate-buffered saline (PBS), stored and protected from light in stock solutions of 89.0 and 249.7 μM at 4°C, respectively.

**Cytotoxicity assay.** DU-145 and NTERA-2 cell lines were seeded in quadruplicates (50,000 cells/well) into 96-well plates and allowed to recover for 24 h. Cultures (70-80% confluent) were incubated in 200 μl of media containing different drug concentrations (final concentrations ranged from 0.1 to 20.0 μM) for 1 h. Cells were then washed with PBS and allowed to recover in serum-containing media for 48 h. Cell viability was determined using MTS CellTiter 96®AQueous One Solution Cell Proliferation Assay (Promega). Briefly, 20 μl of [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-methoxphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, inner salt; MTS] and an electron-coupling reagent (phenazine ethosulfate; PES) were added to each well. Plates were incubated for 1-3 h at 37°C in a humidified 5% CO$_2$ atmosphere. Absorbance was recorded at 490 nm using an ELISA plate reader (Bio-Rad). The IC$_{50}$ was determined from the dose-response curves of three different experiments.

**DNA fragmentation assay.** DNA extracts were prepared from adherent and floating DU-145 and NTERA-2 cells treated with the IC$_{50}$ concentrations of AP-10 and AP-11, using a DNA laddering kit provided by Cayman Chemicals (Ann Arbor, MI). Samples were analyzed on 2% agarose minigel and visualized with ethidium bromide under ultraviolet light.

**Cell death vs. cell growth inhibition.** Under the assumption that AP-10 and AP-11 act similarly on the two cell lines, DU-145 cells (5x10$^4$ cells/well) were seeded in duplicate in 6-well plates and incubated for 48 h under the conditions previously described. Cells were exposed for 1 h to AP-10 or AP-11 using the IC$_{50}$ concentrations determined by MTS assay and allowed to recover for 48 h in serum-containing media. Cell viability was determined by a trypan blue dye exclusion assay. Cell counts of two random wells were performed during plating to confirm the uniformity of cell distribution and to establish the actual initial number of cells plated, and 48 h later before drug exposure to confirm the population doubling time (PDT).

**Cell recovery.** In order to determine whether treatment with AP-10 was reversible and if so how rapidly cells would recover from the cytotoxic effect, logarithmically growing DU-145 and NTERA-2 cells (5x10$^4$ cells/well) were seeded...
in duplicate in 6-well plates and incubated for 48 h. Cells were then exposed for 1 h to their respective IC50 concentration of AP-10. After exposure, the cells were washed with PBS and incubated with media containing 10% CSFBS in the absence or presence of 1.0 μM dihydrotestosterone (DHT) or testosterone (T) for 5 days. To ensure a proper nutrient content and effective drug concentration the medium was replaced daily. Steroids were used in an ethanol vehicle, did not exceed 0.1% (v/v) in the final culture media. Cell viability was determined every 24 h for 5 days by trypan blue dye exclusion assay.

**Results**

**Determination of the cytotoxic activity of AP-10 and AP-11 on NTERA-2 (testicular) and DU-145 (prostate) cancer cells in vitro.** NTERA-2 human testicular and DU-145 human prostate cancer cells were treated with a range of concentrations of AP-10 or AP-11 for 1 h. The cytotoxic activity was then determined using the standard MTS assay. The two analogues inhibited cell growth with IC50 values that ranged between 0.2 and 3.2 μM (Table I). In general, AP-10 showed a higher cytotoxicity than AP-11 and lower IC50 values were observed in the NTERA-2 cell line.

**DNA fragmentation assay.** To determine whether apoptosis was the underlying cellular mechanism by which AP-10 and AP-11 exerted their cytotoxicity, prostate and testicular cells were exposed to AP-10 or AP-11 for 1 h. DNA was extracted from adherent and floating cells 48 h after exposure and subjected to electrophoresis on a 2% agarose gel. No DNA laddering was observed in either cell line exposed to either compound (data not shown). Concerned with the possibility of having extracted the DNA past a time point where DNA fragmentation could be observed, we decided under the assumption that AP-10 and AP-11 act similarly on the two cell lines, to extract DNA only from DU-145 at 6, 12 and 24 h after exposure to AP-10 or AP-11. Fig. 2 shows the results of the DNA fragmentation assay using only DU-145 samples, where we again observed an intact DNA with no indication of degradation or fragmentation. These results suggest that apoptosis was not the underlying cellular mechanism by which these compounds inhibited cell growth.

**Cell death vs. cell inhibition.** Since no evidence of apoptosis was observed, we wanted to differentiate between the cytotoxic and cytostatic effects of AP-10 and AP-11. In order to do this, DU-145 cells were incubated in the presence of the analogues inhibited cell growth with IC50 values that ranged between 0.2 and 3.2 μM (Table I). In general, AP-10 showed a higher cytotoxicity than AP-11 and lower IC50 values were observed in the NTERA-2 cell line.

**Effect of testosterone and dihydrotestosterone on DU-145 and NTERA-2 cells.** In order to determine whether the anthrapyrazole analogue treatment was reversible and if so how rapidly cells would recover from the cytotoxic effect,
DU-145 and NTERA-2 cells were exposed to the IC50 of AP-10 (0.4 and 0.2 μM, respectively) and incubated as described in Materials and methods. As expected, the cells exposed to AP-10 were unable to recover compared to the untreated cells. As seen in Fig. 4A, cells incubated in media containing testosterone, DHT or 10% CSFBS showed a growth rate of 1.03x10^5, 7.6x10^4 and 7.4x10^4 cells/day, respectively. In contrast, the growth rate of untreated cells was determined to be 2.86x10^5 cells/day (3-4 fold increase).

When comparing the growth rate of NTERA-2, we observed that testosterone increased the growth rate by almost 3-fold when compared to the cells incubated in media containing 10% CSFBS (6.2x10^5 vs 2.25x10^5 cells/day). Notably, DHT, a more potent androgen, increased the growth rate only marginally (3.8x10^5, 1.7-fold) when compared to 10% CSFBS. As expected, cells that were not exposed to AP-10 and kept in DMEM/10% FBS throughout the entire experiment, showed the fastest growth rate (8.5x10^5 cells/day).

**Discussion**

The present study attempted to look at the in vitro cytotoxic effect of the anthrapyrazole analogues AP-10 and AP-11 on human prostate cancer (DU-145) and testicular carcinoma (NTERA-2) cells. Using an MTS assay, the IC50 value of AP-10 on the NTERA-2 and DU-145 cells was determined to be 0.2 and 0.4 μM, respectively. In contrast, AP-11 inhibited cell growth with an IC50 value of 1.2 μM (NTERA-2) and 3.2 μM (DU-145). Previous studies in our laboratory had determined that there is approximately a 2-fold difference in the cytotoxic activity of AP-10 compared to AP-11 among breast (MCF-7), endometrial (HEC 1A) and ovarian SK-OV-3 cancer cell lines (unpublished data). In contrast, in the present study we observed a 6- to 8-fold difference between the IC50 values of AP-10 and AP-11 indicating that AP-10 has a higher cytotoxic activity than AP-11. Furthermore, NTERA-2 cancer cells appeared to be slightly more susceptible to the cytotoxic effect of these compounds. A study by Begleiter et al (12) showed AP-10 to have a greater cytotoxicity than AP-11 (5- to 23-fold difference) in breast (MCF 7) and pharynx squamous (FaDu) carcinoma cells, but a lower cytotoxicity in Chinese hamster ovarian (CHO) cells, while in the same study, AP-10 and AP-11 had similar cytotoxic effects in the human leukemia cell line (K562). Although a 2-fold difference may not be biologically relevant, a difference of 8-fold is noteworthy. One possible reason for the difference in the cytotoxicity of the compounds among the different cell lines may be due to the presence of metabolic enzymes that would render the particular anthrapyrazole analogue inactive. Thus increased concentrations may be needed to promote cell death at levels of 50%. In this study it appears that the addition of a methyl group at R4 on the N-2 side chain on AP-11 decreases its ability to interact with DNA or increases its vulnerability for metabolism, resulting in the lower cytotoxic effect observed in the two cell lines.

In order to determine whether apoptosis was the underlying cellular mechanism behind the observed cytotoxic effect of AP-10 and AP-11, DNA was extracted from DU-145 and NTERA-2 cells 48 h after exposure to the IC50 concentration of the analogues. We did not observe the typical 180-200 bp units expected should apoptosis have occurred. The absence of DNA laddering observed in this study may have resulted from extracting DNA from surviving cells that had enough time to recover and re-establish growth. Therefore, to
demonstrated the down-regulation of the cytoxic effect in the cell lines used in this study. It is possible, however, that cells treated with AP-10 or AP-11 may begin programmed cell death, but undergo secondary necrosis, in which case no DNA fragmentation would be observed (20). Another possibility is that AP-10 and AP-11 may arrest cell growth, that is, have a cytostatic rather than a cytotoxic effect.

To test this possibility DU-145 cells were exposed to the IC₅₀ values of AP-10 and AP-11 and cell viability was assessed using trypan blue dye exclusion assay. Our results revealed the expected 50% cell inhibition confirming the cytotoxic effect of the anthrapyrazole analogues. A study by Supino et al (6) demonstrated the ability of the anthrapyrazole BBR 3438 to promote significant cell death only after 144 h of exposure, and suggest delayed apoptosis as the primary mode of cell death. In the present study, cells were exposed for only 1 h followed by DNA extraction 48 h later. Thus, it is possible that in order to observe apoptosis, a longer exposure time to the analogues is needed.

Future studies to determine the biological mechanism by which AP-10 and AP-11 exert their cytotoxicity may include determining whether AP-10 and AP-11 inhibit topoisomerase II and whether its inhibition is correlated with the degree of cytotoxicity observed. However, a study by Begleiter et al (12), failed to demonstrate a correlation between the degree of topoisomerase II inhibition and the cytotoxic effect of all the anthrapyrazoles tested, suggesting that another cellular mechanism may be involved. Several studies have also demonstrated the down-regulation of Bcl-2 that likely reflects an early cellular response to the cytotoxic effect of the drugs, which occurs at a time before substantial cell death can be detected (6,21). Therefore, an analysis of Bcl-2 expression in cells exposed to AP-10 and AP-11 may be valuable.

We were also interested in investigating the effect of hormones via steroid-receptor independent pathways. In vivo effects of anthrapyrazole analogues must take into account the physiological hormonal milieu and their effect on cellular recovery. DU-145 and NTERA-2 cells were exposed to the IC₅₀ values of AP-10 and allowed to recover in the presence or absence of androgens. When comparing the rate of proliferation (cells/day) of DU-145 cells in the presence of testosterone versus the rate seen with DHT or CSFBS, we observed a 1.4-fold increase in the cell growth rate. However, cells exposed to the different treatments did not attain the growth rate seen in the control cells. The lack of hormonal response in the DU-145 is consistent with the absence of androgen receptors in this cell line (9). Therefore, we can conclude that DU-145 cells do not have an alternate receptor-independent pathway. When comparing the growth rate in the NTERA-2 cells, we observed that DHT, a more potent androgen, marginally increased the growth rate when compared to CSFBS. In contrast, testosterone increased the growth rate by almost 3-fold when compared to cells in CSFBS, but the growth rate of testosterone-treated cells did not reach the growth rate observed in the untreated cells. It appears that AP-10 is capable of promoting cell death. However, upon removal, the surviving cells have the capacity to proliferate in the absence of androgens. Under physiological conditions the testis are constantly exposed to concentrations of androgens that may promote growth after treatment with anthrapyrazole analogues but at a slower rate.

In conclusion, our results demonstrate that AP-10 has a higher cytotoxicity than does AP-11 on DU-145 and NTERA-2 cells, and their cytotoxicity results in cell death. However, apoptosis appears not to be involved in mediating the biological activity of these compounds.

Acknowledgements

This work was partially supported by the Fleming Fund, southwestern University. The authors are indebted to Dr Frank Guziec for providing the anthrapyrazole analogues, to Dr Romi Burks and Dr Martin Gonzalez for their graphic technical help and Dr Maria Todd for her technical expertise.

References

4. Fry DW, Boritzi TJ, Besserer JA and Jackson RC: In vitro DNA strand scission and inhibition of nucleic acid synthesis in L 1210 leukemia cells by a new class of DNA complexes the ana 